Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies.
A method has been developed for the quantitation of ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma. ABT-751 and metabolites were separated from endogenous material on a C18 column with acetonitrile-ammonium acetate (2 mM) mobile phase containing formic acid (0.1%, v/v) using isocratic flow for 5 min. The analytes were monitored by tandem-mass spectrometry. Calibration curves were generated over the range of 20-5,000 ng/ml for ABT-751, ABT-751 glucuronide, and ABT-751 sulfate. A 20,000 ng/ml sample that was diluted 1:10 (v/v) with plasma was accurately quantitated. The method has been successfully applied to study the plasma pharmacokinetics of ABT-751 in humans.
Rudek
Michelle A
MA
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. mrudek2@jhmi.edu
Zhao
Ming
M
He
Ping
P
Messersmith
Wells A
WA
Baker
Sharyn D
SD
D050256:Antimitotic Agents / Q000097:blood* / Q000737:chemistry; D002138:Calibration; D002853:Chromatography, Liquid / Q000379:methods*; D019963:Clinical Chemistry Tests; D006801:Humans; D015394:Molecular Structure; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000097:blood* / Q000737:chemistry; D053719:Tandem Mass Spectrometry / Q000379:methods*
C490492:ABT751; D050256:Antimitotic Agents; D013449:Sulfonamides